TABLE 1.

IL‐23 targeting drugs approved (or registered for approval) for psoriatic arthritis (PsA)

Generic name (Trade name)	Target	Approved or in phase 3 studies	Licenced dose for PsA
Ustekinumab (Stelara)	p40 subunit of IL‐23 and IL‐12	Psoriasis, PsA, Crohn's disease, ulcerative colitis	SC: 45 mg at weeks 0 and 4, then every 12 weeks.
		Phase 3 stage: Dermatomyositis polymyositis, Vasculitis	If co‐existent severe psoriasis or weight >100 Kg: recommended dose is 90 mg instead of 45 mg
Guselkumab (Tremfya)	p19 subunit of IL‐23	Psoriasis, PsA	SC: 100 mg at weeks 0 and 4, then every 8 weeks
		Phase 3 stage: Crohn's disease, ulcerative colitis
Risankizumab (Skyrizi)	p19 subunit of IL‐23	Psoriasis, PsA, Crohn's disease	SC: 150 mg at weeks 0 and 4, then every 12 weeks
		Phase 3 stage: ulcerative colitis
Tildrakizumab (Illumetri)	p19 subunit of IL‐23	Psoriasis, PsA a	Not yet approved (psoriasis: SC 100–200 mg at weeks 0 and 4, then every 12 weeks)

Abbreviations: mg, milligrammes; PsA, psoriatic arthritis; SC, subcutaneous.

^a Pre‐registration phase.